45 active not recruiting. 45 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 45 | Active not recruiting 45 |
| Phase 2 | 4 | Active not recruiting 4 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 220 | 2026-08-11 | 2026-10-22 |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines Remibrutinib, Remibrutinib matching placebo, Dupilumab - Chronic Spontaneous Urticaria (CSU) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 409 | 2025-07-11 | 2026-10-13 |
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) DBV712 250 mcg, Placebo - Allergy, Peanut Allergy | Phase 3 | Active not recruiting | DBV Technologies | 480 | 2025-06-24 | 2026-07-22 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis Ruxolitinib, Vehicle Cream - Atopic Dermatitis | Phase 3 | Active not recruiting | Incyte Corporation | 159 | 2025-06-17 | 2026-08-19 |
| A Study of Navenibart in Participants With Hereditary Angioedema navenibart, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Astria Therapeutics, Inc. | 157 | 2025-03-20 | 2026-06-30 |
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 3 | Active not recruiting | Intellia Therapeutics | 80 | 2025-01-15 | 2026-10-08 |
| Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis Placebo, Upadacitinib - Atopic Dermatitis | Phase 3 | Active not recruiting | AbbVie | 99 | 2024-12-22 | 2026-02-23 |
| Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Pharvaris Netherlands B.V. | 81 | 2024-12-01 | 2026-02-13 |
| Oral Intake of Mg in Controlled Asthmatic Patients Magnesium, ICS+LABA - Bronchial Asthma | Phase 2 / Phase 3 | Active not recruiting | Zagazig University | 166 | 2024-11-02 | 2025-08-14 |
| To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis TQH2722 injection, Placebo of TQH2722 injection - Atopic Dermatitis | Phase 3 | Active not recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 500 | 2024-10-08 | 2026-04-20 |
| Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) - Severe Asthma | Phase 3 | Active not recruiting | AstraZeneca | 310 | 2024-09-30 | 2026-10-13 |
| A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis Upadacitinib, Dupilumab - Atopic Dermatitis | Phase 3 | Active not recruiting | AbbVie | 699 | 2024-08-19 | 2026-10-16 |
| Study of CM310 in Adolescent Subjects With Atopic Dermatis CM310 - Atopic Dermatitis | Phase 3 | Active not recruiting | Keymed Biosciences Co.Ltd | 180 | 2024-08-02 | 2025-10-02 |
| Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis LP-003, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Longbio Pharma | 546 | 2024-08-01 | 2025-12-26 |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Celldex Therapeutics | 976 | 2024-07-19 | 2026-03-25 |
| A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria barzolvolimab, Matching placebo - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Celldex Therapeutics | 963 | 2024-07-11 | 2026-03-25 |
| A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Lebrikizumab, Placebo - Dermatitis, Atopic, Eczema | Phase 3 | Active not recruiting | Almirall, S.A. | 520 | 2024-07-03 | 2026-04-21 |
| A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose - Atopic Dermatitis | Phase 3 | Active not recruiting | AbbVie | 184 | 2024-06-14 | 2026-10-16 |
| A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis Amlitelimab, Placebo - Dermatitis Atopic | Phase 3 | Active not recruiting | Sanofi | 1541 | 2024-05-08 | 2026-07-10 |
| A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) LY3650150, Placebo, Standard therapy for INCS - Perennial Allergic Rhinitis (PAR) | Phase 3 | Active not recruiting | Eli Lilly and Company | 450 | 2024-04-26 | 2026-10-27 |
Showing 20 of 45. Sign in to see all of them.
Dermatitis, Atopic (12) · Asthma (9) · Chronic Urticaria (7) · Angioedemas, Hereditary (5) · Food Hypersensitivity (4) · Eczema (3) · Peanut Hypersensitivity (3) · Dermatitis (2) · Eosinophilic Esophagitis (2) · Nut and Peanut Hypersensitivity (2) · Pulmonary Eosinophilia (2) · Rhinitis, Allergic, Seasonal (2) · Sarcoidosis (2) · Angioedema (1)
Immune System Diseases (45) · Hypersensitivity, Immediate (42) · Skin and Connective Tissue Diseases (28) · Skin Diseases (27) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Genetic Diseases, Inborn (17) · Respiratory Tract Diseases (13) · Skin Diseases, Eczematous (13) · Skin Diseases, Vascular (13) · Dermatitis (12) · Respiratory Hypersensitivity (12) · Skin Diseases, Genetic (12) · Urticaria (12) · Lung Diseases (10)
remibrutinib (5) · Adrenal Cortex Hormones (4) · dupilumab (4) · upadacitinib (4) · Albuterol (2) · Budesonide (2) · lebrikizumab (2) · tezepelumab (2) · Adalimumab (1) · Betamethasone Valerate (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Calcineurin Inhibitors (1) · EpiCeram (1) · Fluticasone (1) · IONIS-PKK-LRx (1)
Novartis Pharmaceuticals (5) · AbbVie (4) · AstraZeneca (3) · DBV Technologies (3) · Sanofi (3) · Celldex Therapeutics (2) · Eli Lilly and Company (2) · Almirall, S.A. (1) · Areteia Therapeutics (1) · Assistance Publique - Hôpitaux de Paris (1) · Astria Therapeutics, Inc. (1) · BioCryst Pharmaceuticals (1) · Bristol-Myers Squibb (1) · Dr. Falk Pharma GmbH (1) · Dr. Grace Parraga (1)
United States (31) · Canada (28) · Spain (27) · Germany (25) · United Kingdom (23) · Italy (22) · France (21) · Poland (21) · Australia (19) · Argentina (17) · South Korea (17) · China (16) · Brazil (14) · Israel (14) · Japan (14)
Adrian J Lowe, Doctorate (1) · Alfredo J Lucendo, MD, PhD (1) · Grace E Parraga, PhD (1) · Jolanta Bernatoniene, MD (1) · Mona Bafadhel, MD (1)
PMID 30867201, PMID 34023009, PMID 35714786, PMID 36333616, PMID 36754548, PMID 37043227, PMID 37247226, PMID 37691437, PMID 39393433, PMID 39441580, PMID 40673861, PMID 40716738, PMID 40875187, PMID 40900410, PMID 41767175, PMID 41854973, PMID 42294842, PMID 42530735
2023 (9), 2017 (1), 2025 (1)